Drug Profile
Research programme: cancer and chronic wounds therapeutics - Aurealis Pharma
Alternative Names: AUP 100 series; AUP 500 seriesLatest Information Update: 28 Mar 2020
Price :
$50
*
At a glance
- Originator Aurealis Pharma
- Class Bacteria; Probiotics
- Mechanism of Action Bacteria replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Chronic wounds
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for research development in Cancer in Finland
- 28 Mar 2020 No recent reports of development identified for research development in Chronic-wounds in Finland
- 15 Feb 2016 Early research in Cancer in Finland (unspecified route)